Search

Displaying results 2621 - 2630 of 5925 in total
  1. Drug

    Gefapixant

    go.drugbank.com/drugs/DB15097
    Approved

    [L48596,L48591] It is the first therapy to be approved for the treatment of RCC or UCC in the EU.[L48601] … It received approval in both Japan and Switzerland in 2022 for the treatment of adult patients with RCC and UCC, and received subsequent approval in the EU in September 2023 for the same indications.

    Categories: P-glycoprotein substrates
  2. Drug

    Autologous cultured chondrocytes

    go.drugbank.com/drugs/DB10997
    ApprovedInvestigational

    Autologous cultured chrondrocytes are used as autologous cell therapy to repair articular cartilage injuries in the knee (femoral condyle) due to acute or repetitive trauma.

  3. Drug

    Atidarsagene autotemcel

    go.drugbank.com/drugs/DB17538
    ApprovedInvestigational

    [L45191] Libmeldy was granted orphan designation by the EMA in April 2007, and was issued a marketing authorization in the EU in December 2020 for the treatment of certain manifestations of metachromatic

  4. Drug

    Chlormadinone acetate

    go.drugbank.com/drugs/DB15903
    ApprovedWithdrawn

    [L43942,L42975] Chlormadinone acetate continues to be used in other countries due to its high contraceptive efficacy and tolerability.[A254422,L33974]

  5. Drug

    Resmetirom

    go.drugbank.com/drugs/DB12914
    ApprovedInvestigational

    On March 14, 2024, it was approved by the FDA as the first treatment of liver fibrosis due to noncirrhotic non-alcoholic steatohepatitis (NASH), which is a form of non-alcoholic fatty liver disease (NAFLD

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C8 Inhibitors
  6. Drug

    Caplacizumab

    go.drugbank.com/drugs/DB06081
    ApprovedInvestigational

    Caplacizumab was developed by Ablynx, a Sanofi company and FDA approved on February 6, 2019,[L5302] and approved previously by the EU in October 2018 as a combination therapy with plasma exchange and immunosuppression

  7. Drug

    Dextropropoxyphene

    go.drugbank.com/drugs/DB00647
    ApprovedIllicitWithdrawn

    Due to the risk of cardiac arrhythmias and overdose, possibly leading to death, dextropropoxyphene has been withdrawn from the market in Europe and the United States.

    Synonyms: d-PropoxypheneCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 Inhibitors
  8. Drug

    TU-100

    go.drugbank.com/drugs/DB12467
    Investigational

    TU-100 has been used in trials studying the treatment of Abdominal Pain, Colonic Transit, Crohn's Disease, Rectal Sensation, and Gastric Emptying, among others.

  9. Drug

    Bisphosphocin Nu-3

    go.drugbank.com/drugs/DB16015
    Investigational

    Bisphosphocin Nu-3 is under investigation in clinical trial NCT02737722 (Topically Applied Bisphosphocin Nu-3 on Infected Diabetic Ulcers of Subjects With Type I or II Diabetes Mellitus).

    Synonyms: Nu-3, Bisphosphocin Nu-3
  10. Drug

    JSM 6427

    go.drugbank.com/drugs/DB06139
    Investigational

    JSM 6427 is the first small molecule alpha5beta1 integrin receptor antagonist of its kind to be developed. It has been biologically validated for therapeutic use in the prevention and treatment of wet AMD, the leading cause of blindness ...